Characterization of hyaluronan synthase expression and hyaluronan synthesis in bone marrow mesenchymal progenitor cells: predominant expression of HAS1 mRNA and up-regulated hyaluronan synthesis in bone marrow cells derived from multiple myeloma patients

被引:52
作者
Calabro, A
Oken, MM
Hascall, VC
Masellis, AM
机构
[1] Abbott NW Hosp, Virginia Piper Canc Inst 39419, Minneapolis, MN 55407 USA
[2] Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA
关键词
D O I
10.1182/blood-2002-01-0030
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hyaluronan (HA) is suggested to play a role In the pathophysiology of multiple myeloma. To further investigate the role of HA in this disease, we examined hyaluronan synthase (Has) gene expression and HA production In bone marrow mesenchymal progenitor cells (bmMPCs) derived from multiple myeloma patients. The relative abundance of mRNA for each HAS gene was determined using competitive reverse transcription-polymerase chain reaction (cRT-PCR), whereas HA production was detected by fluorophore-assisted carbohydrate electrophoresis (FACE). We determined the basal expression of Has isoforms In myeloma bmMPCs and then compared this expression with expression In healthy donor bmMPCs. Of the 3 Has isoforms, Has1 mRNA was expressed predominantly In myeloma bmMPCs, with expression 7.6-fold greater than Has2. Compared with normal bmMPCs, Has1 mRNA expression was 20-fold greater In myeloma bmMPCs. Normal bmMPCs predominantly expressed Has2 mRNA (8.2-fold greater than myeloma bmMPCs). Upon coculture of myeloma bmMPCs with plasma cells, Has1 transcript was strongly attenuated, FACE results show that myeloma bmMPCs synthesize 5.7-fold more HA than those from healthy donors. These data suggest that myeloma bmMPCs could be an Important component of the myeloma pathophysiology in vivo by their increased expression of extracellular matrix (ECM) components relevant to plasma cell growth and survivat. (C) 2002 by The American Society of Hematology.
引用
收藏
页码:2578 / 2585
页数:8
相关论文
共 39 条
[1]   CONNECTIVE-TISSUE COMPONENTS IN SERUM IN MULTIPLE-MYELOMA - ANALYSES OF PROPEPTIDE OF TYPE-I AND TYPE-III PROCOLLAGENS, TYPE-I COLLAGEN TELOPEPTIDE, AND HYALURONAN [J].
ABILDGAARD, N ;
NIELSEN, JL ;
HEICKENDORFF, L .
AMERICAN JOURNAL OF HEMATOLOGY, 1994, 46 (03) :173-178
[2]  
BORSET M, 1994, EUR J HAEMATOL, V53, P31
[3]   Microanalysis of enzyme digests of hyaluronan and chondroitin/dermatan sulfate by fluorophore-assisted carbohydrate electrophoresis (FACE) [J].
Calabro, A ;
Benavides, M ;
Tammi, M ;
Hascall, VC ;
Midura, RJ .
GLYCOBIOLOGY, 2000, 10 (03) :273-281
[4]   Adaptation of FACE methodology for microanalysis of total hyaluronan and chondroitin sulfate composition from cartilage [J].
Calabro, A ;
Hascall, VC ;
Midura, RJ .
GLYCOBIOLOGY, 2000, 10 (03) :283-293
[5]  
CALIGARISCAPPIO F, 1991, BLOOD, V77, P2688
[6]   Biology of bone marrow stroma [J].
Clark, BR ;
Keating, A .
BONE MARROW TRANSPLANTATION: FOUNDATIONS FOR THE 21ST CENTURY, 1995, 770 :70-78
[7]   Serum hyaluronan in patients with multiple myeloma: Correlation with survival and Ig concentration [J].
Dahl, IMS ;
Turesson, I ;
Holmberg, E ;
Lilja, K .
BLOOD, 1999, 93 (12) :4144-4148
[8]   Integrin-mediated drug resistance in multiple myeloma [J].
Damiano, JS ;
Dalton, WS .
LEUKEMIA & LYMPHOMA, 2000, 38 (1-2) :71-81
[9]   Hyaluronan: Fundamental principles and applications in cancer [J].
Delpech, B ;
Girard, N ;
Bertrand, P ;
Courel, MN ;
Chauzy, C ;
Delpech, A .
JOURNAL OF INTERNAL MEDICINE, 1997, 242 (01) :41-48
[10]   CD44 isoforms are differentially regulated in plasma cell dyscrasias and CD44v9 represents a new independent prognostic parameter in multiple myeloma [J].
Eisterer, W ;
Bechter, O ;
Hilbe, W ;
van Driel, M ;
Lockhorst, HM ;
Thaler, J ;
Bloem, AC ;
Günthert, U ;
Stauder, R .
LEUKEMIA RESEARCH, 2001, 25 (12) :1051-1057